Clinical Trials
17 trialsNCT01384513 2026-04-15
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05714345 2026-03-02
EXPAND
Allogene Therapeutics
Phase 2 Terminated
NCT06253663 2025-12-16
JKART-1
Gilead Sciences
Phase 2 Active not recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
NCT06802315 2025-06-25
BMT-13
University of Illinois at Chicago
Phase 2 Recruiting
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT06367114 2024-04-19
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 2 Unknown
NCT02859402 2022-08-18
RRTCLAlloSCT
Keimyung University Dongsan Medical Center
Phase 2 Recruiting
NCT00169208 2019-08-28
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01173679 2017-04-14
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL
Massachusetts General Hospital
Phase 2 Terminated
NCT00683046 2016-11-22
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Phase 2 Completed
NCT01578343 2016-04-15
ZOLINZA
Samsung Medical Center
Phase 2 Terminated
NCT00615589 2016-04-04
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00393107 2006-10-26
Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
Gruppo Italiano Studio Linfomi
Phase 2 Completed